Effects of low-dose baclofen adjuvant therapy on patients with trigeminal neuralgia and its effects on inflammatory factors and oxidative stress
10.12092/j.issn.1009-2501.2020.03.012
- VernacularTitle: 低剂量巴氯芬辅助治疗对三叉神经痛患者的疗效及对炎症因子,氧化应激反应的影响
- Author:
Zhibing PI
1
Author Information
1. Department of Pain Treatment, The First Affiliated Hospital of Wenzhou Medical University
- Publication Type:Journal Article
- Keywords:
Baclofen;
Inflammatory factors;
Oxcarbazepine;
Oxidative stress reaction;
Trigeminal nerve
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(3):317-322
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To study the effect of low-dose baclofen on inflammatory factors and oxidative stress in patients with trigeminal neuralgia. METHODS: A total of 112 patients with trigeminal neuralgia treated in our hospital from Jan. 2017 to Jan. 2019 were selected as the subjects; they were divided into test group (n=56) and control group (n=56) according to random number table method. The control group was treated with oxcarbazepine, while the test group was treated with low-dose baclofen on the basis of the control group; the clinical total effective rate, visual analogue scale (VAS), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) levels and the incidence of adverse reactions were compared between the two groups. RESULTS:The clinical total effective rate of the test group was significantly higher than that of the control group (P<0.05); the VAS score of the two groups was significantly lower than that before treatment (P<0.05), and the VAS score of the test group was significantly lower than that of the control group (P<0.05); the levels of TNF-α, IL-6 and in the two groups were significantly lower than those before treatment (P<0.05), and the levels of TNF-α, IL-6 and in the test group were significantly lower than those in the control group (P<0.05); the levels of MDA in the two groups were significantly lower than those before treatment (P<0.05), SOD and GSH-Px were significantly higher than those before treatment (P<0.05), and the levels of MDA in the test group were significantly lower than those in the control group (P<0.05), while the levels of SOD and GSH-Px were significantly higher than those in the control group (P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). CONCLUSION:Low-dose baclofen adjuvant therapy has good clinical efficacy for patients with trigeminal neuralgia, which can effectively relieve pain, reduce inflammation and oxidative stress.
